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1. Introduction   
The initial idea that exogenous opiates can affect immune function was first floated in 1898 
when Cantacuze described the effect of opium on leukocyte phagocytosis in guinea pig 
model. Recently findings from several investigators (Quaglio et al., 2002; Nath et al., 2002; 
Georges et al., 1999; Vallejo et al., 2004; Roy et al., 2006; Somaini et al., 2008) support the role 
of opiates in suppressing a variety of immunological end points in opiate abusers. 
Endogenous opioids seem to have a physiological role in modulating the Th1/Th2 balance, 
by reducing Th1 and enhancing Th2 representative cytokines. Exogenous opioids, on the 
other hand, seem to display various different modulatory profiles on the immune function, 
according to the drug under consideration. In this regard, available evidence shows that 
while morphine and heroin are liable to attenuate the immune response, long-acting opioids 
that are used in withdrawal treatment, such as methadone and buprenorphine, are largely 
devoid of immunosuppressive activity. Opioids can also influence the immune function 
through the activation of the descending pathways of the hypothalamus-pituitary axis 
(HPA) and the sympathetic nervous system (Vallejo et al., 2004). This review on role of 
opioidergic system in humoral immune response summarizes the effect of opiate receptor 
polymorphism on innate and adaptive immunity, identifies the role of the mu opioid 
receptor in these functions, and finally discusses how changes in these parameters may 
increase the risk for opportune infections in drug dependent subjects or attenuate the 
symptoms of rheumatoid arthritis. 
2. Immune system and immune response 
The immune system is composed of many interdependent cell types that collectively protect 
the body from bacterial, parasitic, fungal, viral infections and from the growth of tumor 
cells. Many of these cell types have specialized functions. The cells of the immune system 
can engulf bacteria, kill parasites or tumor cells, or viral-infected cells. The immune system 
protects us from potentially harmful substances by recognizing and responding to their 
presence, invoking a specific and targeted response. An immune response is thus the 
mechanism by which the body recognizes and defends itself against foreign or non-self 
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substances and organisms such as bacteria, viruses, and other substances that appear 
harmful to the body. Taken together these substances are known as antigens and the 
immune system recognizes and destroys substances that contain any antigens.  
Immune system works as a layered defence system of increasing specificity. It can be 
divided into two major components:  
• The Innate immune system forming the first line of defence providing an immediate, 
non-specific response (Litman et al., 2005)  
• The Adaptive immune system, which becomes activated in case of failure/inadequacy 
of the innate immunity to contain the infection,  recognizes the pathogen mounting a 
specific response, leading to formation of an immunological memory, enabling a 
stronger and faster response each time this pathogen is re-encountered (Mayer, 2006) in 
the life course of the individual. 
The role of innate and adaptive immunity is tabulated below:  
 
Function/Immunity  Innate  Adaptive Immunity 
Kinetics Immediate  Delayed 
Nature of Response   Non –Specific  Specific 
Cells Types Involved Leucocytes : NK cells, 
Basophils, Mast cells 
Lymphocytes: T-cells and B-cells 
Immune memory No immunological memory 
on exposure 
Immunological memory is 
generated on exposure 
Receptor 
Reorganization 
Limited number of target  
conserved   domains 
Larger number of  both 
conserved and novel domains 
Table 1. Differences between Innate and Adaptive immunity 
An immune response to foreign antigen requires the presence of an antigen-presenting cell 
(APC), (usually either a macrophage or dendritic cell) in combination with a B cell or T cell. 
When an APC presents an antigen on its cell surface to a B cell, the B cell is signalled to 
proliferate and produce antibodies that specifically bind to that antigen and become an 
agent for removal of the antigen from the host organism. 
3. Humoral response and its role 
Humoral immunity is so named because it involves substances found in the humours, or 
body fluids. It is mediated by antibodies produced by cells of the B lymphocyte lineage. B 
cells, activated by the adaptive immune responses, transform into plasma cells which 
secrete antibodies. This process is aided by CD4+ T-helper 2 cells, which provide active 
co-stimulation. The secreted antibodies bind to antigens present on the surfaces of 
invading microbes, which marks them for subsequent destruction (Pier et al., 2004). 
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Antibodies are glycoproteins belonging to the molecular superfamily of immunoglobulins 
which are often used interchangeably. In structure, they are large Y-shaped globular 
proteins and are classified into five types: IgA, IgD, IgE, IgG, and IgM. Each 
immunoglobulin class differs in its biological properties in targeting different types of 
antigens (Pier et al., 2004). Each antibody recognizes a specific antigen unique to its target. 
By binding their specific antigens, antibodies can cause agglutination and precipitation of 
antigen-antibody products, prime for phagocytosis by macrophages and other cells, block 
viral receptors, and stimulate other immune responses, such as the complement pathway. 
 
Name Type Complex  Primary Function Special properties 
IgA 2 Dimer Prevents gut and airways 
colonization by pathogens 
 
IgD 1 Monomer Functions  as an antigen receptor 
on B-cells  unexposed to antigens 
 
IgE 1 Monomer Binds to allergens and triggers 
histamine release  
 
IgG 4 Monomer Provides the majority of antibody-
based immunity  
Can crossover from 
placenta to provide 
passive immunity 
IgM 1 Pentamer Eliminates pathogens in the early 
stages of B cell mediated IR 
 
Table 2. Antibody types and their functions 
4. Expression of Mu opioid receptor on immune cells 
4.1 Opioid system and its components 
Opioids are chemicals that work by binding to opioid receptors, found in the central and 
peripheral nervous system and the gastrointestinal tract. Opioids play diverse biological 
functions, including reward, analgesia, and stress responsivity (Kreek and Koob, 1998; 
Vaccarino et al., 2000) and have been extensively studied for their therapeutic properties.  
For opioids to be biologically active they must engage with any of the three principal classes 
of opioid receptors, namely, Ǎ, ǋ, ǅ (mu, kappa, and delta). In all about seventeen different 
receptor types are reported, which include the ǆ, Ǌ, ǌ, and Ǉ (Epsilon, Iota, Lambda and Zeta) 
receptors. These receptors share the common feature of binding to opioids/opiates with 
high affinity and classical stereo-selectivity. Cloning of the opioid receptors allowed their 
classification into the super-family of seven trans-membrane domain guanine-protein (G-
protein) coupled receptors and are known to be involved in GABAnergic neurotransmission 
and their activation is reversed by the opioid inverse-agonist naloxone. The opioid receptors 
show a very high degree of sequence similarity at both nucleotide and protein levels. The 
homology  is particularly  striking  in  the  seven  trans-membrane  domains  and  three  
intracellular  loops. The extra-cellular  N-terminal  domain,  three  extra-cellular  loops  and  
the  intra-cellular carboxy-terminal domains are less conserved among the three receptor 
types. Chromosomal locations for the human opioid receptors and opioid peptide genes 
have been established and are summarised in Table 3. 
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Protein  Gene  Location 
Mu opioid recptor OPRM1 6q24-25d 
Kappa opioid recptor OPRK1 8q11.2 e, g 
Delta opioid recptor OPRD1 1p34.3-36.1f 
Preproopiomelanocortin POMC 2p23.3 a, b, h 
Preproenkephalin PENK 8q23-q24c 
Preprodynorphin PDYN 20p12-pterc 
Table 3. Chromosomal locations of human genes coding for opiate receptors & endogenous 
opioid peptides 
Endogenous opioid peptides and their receptors form a neuromodulatory system that 
impacts several physiological processes, such as cognition,  pain control, emotions, response 
to stress, and pathophysiology of both addiction to and immunosuppressive effects of 
opiates (Olson et al., 1996). Despite a number of side effects, such as respiratory depression, 
constipation, tolerance and dependence, morphine remains one of the most valuable 
therapeutic drugs (Schug SA et al., 1992).  
Clinicians have long known that apart from being addictive opiates also cause immuno-
suppression. Present knowledge  of  interaction between opiates and the immune system is 
based on pharmacological studies and several mechanisms have been proposed. In vitro 
experiments suggest that opiates act directly upon immune cells (Sibinga and  Goldstein, 
1988; Chuang et al., 1995). Some reports indicate detectable expression of Ǎ opioid receptor 
(MOR) mRNA in immune cells suggesting that these cells are targets for direct opioid action 
(Smolka and Schmidt, 1999). Others have proposed the existence of non-classical receptors, 
which specifically bind ǃ-endorphin or recognize alkaloids but not peptidic opioid ligands 
(Pasternak., 1993). Pharmacology of opiates on immune responses seems complex, due to 
presence of a wide diversity of opiate receptors and therefore the molecular basis of opiate 
action on the immune system needs to be further studied.  
Allelic variants in the opioid receptor and/or opioid peptide genes may lead to an altered  
endogenous opioid system. More than 100 polymorphisms have been identified in the 
human OPRM1 gene and at least 10 single nucleotide polymorphisms (SNPs) have been 
reported in OPRM1-translated regions (Bond et al., 1998; Hoehe et al., 2000). Of these 10 
SNPs, the A118G variant (rs 1799971) is the most prevalent and widely studied. The 118G 
allele is reported to increase the affinity of MOR for ǃ-endorphin, an endogenous opiate, 
and activate inwardly rectifying potassium channels with three times greater potency than 
the most prevalent A118 allele (Bond et al., 1998). Although pharmacological studies suggest 
that the inhibitory action of opiates on immunity is mediated by opioid receptors, however  
molecular evidence for individual differences remains elusive.  
4.2 Opioid receptors and immune functions 
Opiates are immunosuppressive drugs and cause a decrease in several immune components 
(Brown et al., 1974). Jankovic and Maric (1987) showed that the neuropeptides, methionine-
enkephalin, leucine-enkephalin, especially the former, exhibit a protective action against 
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anaphylactic shock in rats sensitized to ovalbumin. On the other hand small doses of 
enkephalins stimulated humoral immune responses in rats. Thus, it appears that 
enkephalins both suppress and potentiate immune responsiveness. Naloxone, a blocker of 
opioid receptors, enhanced humoral immune reactions in rats. 
Sibinga and Goldstein (1988) first showed that opioid receptors are expressed on cells from 
the immune system as determined by receptor binding and functional assays. Opioid 
alkaloids and peptides, such as morphine and endogenous opioid peptides, namely β-
endorphin, have been shown to modulate the function of lymphocytes and other cells 
involved in host defence and immunity. Results from several laboratories have indicated 
that opioids can operate as cytokines, the principal communicating signals among the 
immunocytes. Indeed, all of the major properties of cytokines are shared by opioids, i.e., 
production by immune cells with paracrine, autocrine, and endocrine sites of action, 
functional redundancy, pleiotropy, and effects that are both dose and time dependent 
(Peterson et al., 1998). The Ǎ-selective opioid, DAMGO, has been shown to increase the 
release of the monocyte chemoattractant protein-1 (MCP-1), RANTES, and interferon-Ǆ from 
human peripheral mononuclear cells. Buprenorphine, another compound, known to have 
both agonist and antagonist properties at the MOR, has been shown to suppress splenic NK-
cell activity, lymphocyte proliferation, and IFN-Ǆ production in rats in a naltrexone-
reversible manner suggesting a role of MOR in immune-modulations (Bidlack, 2006). 
Opiates like morphine, heroin, fentanyl and methadone are known to induce immune-
suppression and affect both innate and adaptive immunity defining a role of MOR in these 
functions (Roy et al., 2006). Immune cells at different stages of differentiation express MOR 
differentially. Morphine affects the development, differentiation and function of various 
immune cells (Roy et al., 2006). Opiates directly bind to both classical and non-classical 
opioid receptors on immune cells and thus modulate their function. They also bind to 
classical opioid receptors in the CNS, causing the release of catecholamines and/or steroids, 
which in turn further affect the immune cell functions. They play a role in suppressing a 
variety of immunological end points such as proliferation, functions and responses of both T 
and B cells and attenuating the cytokine system (Vallejo et al., 2004;). They also suppress 
movement and number of circulating white blood cells (Miyagi et al., 2000; Perez-Castrillon 
et al., 1992). 
5. Clinical observations  
5.1 In opiate dependent subjects 
 Heroin addicts have been repeatedly documented to have an increased susceptibility to a 
variety of infectious diseases, and also depict alterations in a wide variety of immune cell 
parameters. These subjects manifest a variety of changes in the immune system indicative of 
both decreased and increased immune responses. While the absolute number and 
percentage of total and active T lymphocytes in the peripheral blood of opiate addicts and T-
cell rosette formation were found to be significantly depressed in one study, an increase in 
the absolute number of T-cells in the blood of heroin addicts was reported in another. 
Similar conflicting results have been reported concerning the functional activity of T 
lymphocytes from heroin addicts. Brown et al. (1974) found impaired responsiveness, in 
vitro, of lymphocytes to each of the three mitogens (PHA, concavanalin A, pokeweed 
mitogen) in heroin addicts relative to control values but another group reported normal T-
proliferative responses to both concavanalin A and tetanus toxoid antigen in another group 
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of healthy addicts. Immunophenotypic markers on lymphoid cells in human addicts have 
been studied using flow-cytometric analysis and a profound decrease in the T-
helper/cytotoxic T- cell (CD4/CD8) ratio in heroin addicts as well as a normal pattern of T-
cell subsets and a normal CD4/CD8 ratio in another group of healthy intravenous drug 
abusers and methadone patients has been reported by separate groups. More, recent studies 
have further established the immunosuppressive effects of opioids. Morphine has been 
shown to antagonize IL-1α and TNF-α induced chemotaxis in human leucocytes as well 
decrease levels of IL-2 and IFN-γ and increase levels of IL-4 and IL-5. They have also been 
shown to suppress expression of antigenic markers on T- helper cells.  
Opiate use is known to depress E-rossette formation, indicating clinical immunosuppression. 
Long-term use of opiates produces atrophy of lymphoid organs, decreases lymphoid 
content, alters antigen-specific antibody production, causes loss of T helper (Th) cells 
(McDonough et al., 1980; Donahoe et al., 1987) and decreases T cell reactivity, T helper/T 
cytotoxic cell ratios and T helper cell function specifically (Thomas et al., 1995; Rouveix, 
1992). Opiates are known to impair both immunoglobulin synthesis, function and induce 
immunonutritional deficiencies (Varela et al., 1997). Humoral immunity can be assessed by 
determining the levels of immunoglobulins, which are antigenic receptors, secreted by B-
cells. Alterations of normal immunoglobulin concentration in opiate users are an indication 
of immunologic impairment (Rho 1972). Alterations in immunoglobulin (Ig) synthesis, 
concentration and function (Thomas et al., 1995; Islam et al., 2004) are indication of 
immunologic impairment in opiate users (Rho, 1972; Islam et al., 2001; 2002).  
 
 
Fig. 1. Serum IgG, IgA levels in Opiate users & Nonusers 
A decrease of IgA levels and increase of IgG and IgM levels has also been reported in Indian 
opiate users as compared to non-users (Naik et al., 2001; Islam et al., 2004). We  used a 
genetic approach to correlate a functional OPRM1 gene polymorphism with known action of 
opiates on immunity and a prospective study was undertaken to address the relationship of 
the A118G variation with the amount of exogenous opiates consumed and correlate the 
immunosuppressive effects of exogenous opiates with the MOR alleletype among opiate-
dependent and control subjects from northern India. We investigated the immune status of 
opiate users by measuring serum Ig (IgG and IgA) levels, in association with specific MOR 
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genotype of the study subjects (Sharad et al., 2007). Our findings confirmed that the mean 
circulating levels of Ig were significantly lower in opiate users when compared with levels in 
cohort controls (Figure 1). Among opiate dependent subjects, individuals with AA 
genotypetype were found to have the lowest levels of circulating Igs, both IgG and IgA 
(p=0.0001) while the AG genotype carrying individuals had a higher level of both Igs. The 
homozygous GG genotype was in between the AA and AG genotypes (Figure 2). 
 
 
Fig. 2. Serum IgG Values in Opiate users and Non-users with different MOR genotypes 
5.2 Auto-antibodies in individuals with different MOR alleles 
Autoantibodies (aAbs) is a greek derived word meaning  against the self as  “auto" means 
"self", "anti" means "against" and "body". They are produced by the immune system but 
recognise the proteins produced in the individual’s own body. The antibodies that usually 
attack the proteins present in the nucleus of the cell are called antinuclear antibodies (ANA). 
It is a known that about 15% of the completely normal population tests positive for ANA. 
The interactions between these receptors and immune system, including autoimmune 
responses, are poorly understood. Granstrem and his co-workers (2006) showed that 
administration of morphine significantly elevate the levels of aAbs to mu delta-opiate 
receptor (MDOR). At the same time psycho-stimulant drug, d-amphetamine, or a commonly 
abused substance, nicotine, had no effect on these aAbs levels. Such observations support 
the hypothesis that, opiates could be common mediators between the nervous and the 
immune system. The high levels of aAbs to MDOR were also observed in heroin self-
administering rats as well as in human addicts and shown as a function of severity of opiate 
addiction (Dambinova and Izykenova, 2002), suggesting that opiate addiction may be 
somehow associated with autoimmune response/processes.  
Koziol  and collègues (1997) compared the range of ANA in "healthy" individuals in 
comparison with patients with autoimmune disorders such as systemic lupus 
erythematosus,  systemic sclerosis, sjogren’s syndrome and rheumatoid arthritis, or soft 
tissue rheumatism. Their findings revealed that in healthy individuals, the frequency of 
ANA did not differ significantly across the 4 age subgroups spanning 20-60 years of age. 
This putatively normal population was ANA positive in 31.7% of individuals at 1:40 serum 
dilution, 13.3% at 1:80, 5.0% at 1:160, and 3.3% at 1:320 (Koziol, 1997). Experiments by 
Bendtzen and co-workers (1993) confirmed the presence of nano-to-picomolar concentrations 
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of high affinity IgG antibody to interleukin 6 (IL-6ab) in sera of 15% normal Danish blood 
donors. The same group had earlier shown presence of detectable autoantibodies against IL-
1ǂ in sera from 10% of normal human subjects (Bendtzen, et al., 1989). 
To study the functional consequences of OPRM1 genotype as early modifiers of auto-
immune response we estimated ANA in opiate dependent subjects with A118 or G118 MOR 
allele (unpublished data; Kapur S and co-workers). A sandwich ELISA assay was performed 
using Nuclear S100 extract prepared from lymphocytes of normal individuals. The whole 
complement of the nuclear fraction was used to increase the antigen repertoire. In order to 
test the impact of OPRM1 genotype, plasma from diagnosed cases of Rheumatoid Arthritis, 
clinically known to have a higher level of circulating ANA, were also tested for comparison. 
True to our projections our findings confirmed significantly higher titres of ANA in the 
rheumatoid arthritis subjects in comparison to those seen in plasma of opiate dependent and 
control subjects. The mean titres of ANA in the different groups are shown in Figure 3. The 
mean anti ANA titres in AA genotype bearing subjects were higher than those observed in 
GG genotype bearing subjects in all three groups studied. 
 
 
Fig. 3. Bar graph showing relative levels of ANA titres in the groups under study 
5.3 Chemokines in relation to MOR genotype 
Chemokines consist of a family of 8-16 kDa cytokines that are generated very early in a wide 
variety of inflammatory responses and attract leukocytes to local sites. At nanomolar 
concentration chemokines initiate signal transduction and activate leukocytes through seven 
transmembrane (STM) receptors, but higher micromolar doses result in homologous 
desensitizing effects. Chemokines along with adhesion molecules orchestrate the migration 
of opioid peptide-containing leukocytes to inflamed tissue. Leukocytes secrete opioid 
peptides under stressful conditions or in response to releasing agents such as corticotropin-
releasing factor and other chemokines. Due to the crucial role of chemokines in recruitment of 
leukocytes to sites of inflammation they play a vital role in a variety of infective/anti-
inflammatory diseases. Chemokines are subdivided according to their structure into two 
subgroups, of which the largest are the CXC, or alpha, and CC, or beta groups defined by the 
presence or absence of an additional amino acid (“X”) respectively between the first two 
cysteine residues in a conserved four cysteine motif. The alpha chemokines are further 
subdivided according to the presence or absence of a glutamine-leucine-arginine (ELR) amino-
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acid sequence near the active site. Those possessing this sequence are potent chemoattractants 
for neutrophils while those that do not possess the motif are chemotactic for lymphocytes. 
 
 
Fig. 4. Mean levels of cytokines (MCP-1and IL-8 values (pg/ml)) in Opiate users and Non-users 
 
 
Fig. 5. MCP-1 Values (pg/ml) in Opiate users and Non-users with different MOR genotypes 
Interleukin 8 (IL-8) possesses an ELR amino acid-sequence and is the prototype alpha 
chemokine, being exclusively chemotactic for neutrophils. IL-8 is produced by macrophages 
and other cell types such as epithelial cells and is also synthesized by endothelial cells, 
which store IL-8 as storage vesicles. IL-8 has potent chemotactic activity at nanomolar and 
picomolar concentrations for neutrophils and lymphocytes, respectively (Larsen et al., 1989) 
and induces leukocyte trans-endothelial transmigration (Zoja et al., 2002). Thus, IL-8 is 
better known for its role in inflammatory diseases, where it attracts white blood cells into an 
area of tissue injury and sites of inflammation. On the basis of reports that opiates have anti-
inflammatory effects and also use STM, it has been postulated that they may cross-
desensitize the response of leukocytes to chemokines. Met-enkephalin (MET) is chemotactic 
for human peripheral blood monocytes. Indeed it has been observed that preincubation of 
monocytes or neutrophils with MET or morphine prevented their subsequent chemotactic 
response to chemokines (MIP1 or IL-8). However, MET does not inhibit the chemotactic 
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response of PMN to NAP-2, a homologous chemokine that is less potent than IL-8 but 
cannot be desensitized. The inhibitory effect of opiates on chemokine-induced chemotaxis 
was also antagonized by naloxone. Since MIP-1 and IL-8, unlike NAP-2, have the capacity to 
desensitize leukocytes, it is reasonable to expect that opiates, by desensitizing some 
chemokine responses, can suppress inflammatory reactions. 
 
 
Fig. 6. IL-8 Values (pg/ml) in Opiate users and Non-users with different MOR genotypes 
Mu opioids have been shown to alter the release of chemokines important for both host 
defence and inflammatory response. Exposure to morphine has been shown to suppress 
production of IFN-ǂ, IL-2 and IL-4 by lymphocytes (Lysle et al., 1993; Geber et al., 1975; 
Bhargava et al., 1994). Wetzel et al., (2000) showed that mu selective agonists increased the 
expression of the CC chemokine, MCP-1. MCP-1 plays a major role in two distinctly 
different host responses: cellular immune reactions and responses to active tissue injury 
(Leonard et al., 1990). MCP-1 can be produced by leukocytes of both lymphocyte and 
monocyte lineages and is specific for monocytes, macrophages and activated T cells. MCP-1 
can both initiate and amplify monocyte recruitment to the microvascular walls, and let 
monocyte enter into the tissues and be transformed into macrophages (Sozzani et al., 1995).  
Recruitment of macrophages into tissues is an important process in inflammation and host 
defence and thus both MCP-1 and IL-8 both play a significant role in inflammation and host 
defence. Mean MCP-1 levels in dependent subjects were 35.87 pg/ml (ranging between 8.95-
80.81 pg/ml) while in non-users it was 24.12 pg/ml (5.87-109.1) and were significantly 
higher in opiate users as compared to control subjects (p = 0.0001, t =6.398). The mean IL-8 
in opiate dependent subjects was 15.08 pg/ml (ranging between 1.580-44.38) and 12.13 
pg/ml (ranged from 3.390-37.60) in control subjects (non users). The levels in addicts were 
significantly higher in comparison to control subjects (p = 0.0061, t = 2.773) as shown in 
Figures 4-6. The presence of 118G allele was found to be associated with increased levels of 
both MCP1 and IL-8 and can be envisaged to play a critical role in chemotactic migration of 
both lymphocytes and neutrophils to site of inflammation and tissue injury. 
6. Observations in cases of therapeutic use of opiates as analgesics  
One of the most frequent conditions for which morphine is used is the treatment of pain. 
Hashiguchi and colleagues (Hashiguchi et al., 2005) published a study with a limited 
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number of patients who were receiving morphine therapy for advanced cancer pain. 
Although not conclusive, this work suggests that both humoral and cellular immunity are 
modulated by morphine and its metabolites during the early phases of therapy, and that 
such immune-modulation can have long-term detrimental effects.  
The immunosuppressive properties of another potent opioid fentanyl have been shown to 
affect cellular immune responses in humans in a dose related manner (Jacobs et al., 1999 & 
Beilin et al., 1996). In another study, patients with a long history of heroin intake when 
switched to high doses of buprenorphine showed significant immuno-suppression. 
Endogenous opiates lead to elevated plasma levels of corticotrophin releasing hormone, 
adrenocorticoid hormone and glucocorticoids, which further lead to immune suppression 
and increased incidence of opportunistic infections.  Inhibitory action of morphine on 
immune responses, demonstrated both in animal models and humans (Quaglio et al., 2002; 
Nath et al., 2002) accounts for increased susceptibility to opportunistic infections in opiate 
dependent subjects (Vallejo et al., 2004).   
MOR is expressed in ileal and colonic enteric neurons as well as in immunocytes such as 
myeloid cells and CD4+ and CD8+ T cells. Specific host defense in the intestine is mediated 
by the gut-associated lymphoid tissue (GALT), which comprises the largest mass of immune 
cells in the body. GALT, which consists of both organized and diffuse lymphoid tissue 
mediates immune protection at both local and distant anatomical sites through local dimeric 
IgA secretion and the ability of lymphocytes activated at one mucosal site to recirculate and 
home to other mucosal surfaces (Mowat & Viney, 1997). Thus, humoral immunity in GALT 
is conveyed by plasma cells committed to IgA synthesis and IgA-producing plasma cells 
circulate throughout the lymphatic system and protect other mucosal surfaces (Croitoru & 
Bienenstock., 1994). Polymeric IgA is transported into epithelial cells via secretary 
component and released into the lumen as secretary IgA (sIgA) where it can neutralize 
viruses and prevent bacterial adherence to the activated mucosa. 
7. Epigenetics and OPRM1 gene 
Genetic studies have revealed the existence of several common susceptibility genes for 
autoimmune/inflammatory disorders. However, genetic variation represents only half of 
the story. Recent studies have unequivocally established that epigenetic mechanisms 
regulate gene expression and are sensitive to external stimuli, bridging the gap between 
environmental and genetic factors. Thus, gene function depends not only on DNA sequence, 
but also on epigenetic modifications, including both DNA methylation and histone post-
translational modifications. These modifications are influenced by environmental factors 
and are known to contribute to the pathogenesis of several autoimmune diseases. Several 
studies have highlighted the importance of the tissue-specificity of DNA methylation 
changes. Over and above the expression of basic genetic variability, the contribution of 
genetic factors to disease risk can be modulated by the environment. A number of internal 
and external environmental factors have been associated with the etiopathology of 
inflammatory disorders, including viral infection, nutrition, and exposure to chemicals and 
radiation. Such factors influence or modify the profile of epigenetic modifications, which, in 
turn, have a direct relationship with the regulation of gene expression, and ultimately the 
function of the immune system. Active demethylation has been described, particularly in 
cell (de)differentiation and reprogramming processes, and in the context of the activation of 
immune cells (Bhutani et al., 2010; Bruniquel & Schwartz., 2003). The first suggestions of a 
potential role for DNA methylation in autoimmune disease came from studies in which 
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small compounds that result in decreased DNA methylation, such as 5-azacytidine, 
hydralazine or procainamide, induced symptoms that are associated with autoimmune 
disease. For example, these drugs induce autoreactivity in CD4+ T cells, or antinuclear factors 
in both human and mouse models (Cannat & Seligmann, 1968; Richardson, 1986; Cornacchia  
et al. , 1988). Most of the genes for which DNA hypomethylation has been reported are from 
the cluster of differentiation (CD) group, including ITGAL (also known as CD11A), (Lu et al., 
2002) which is important for cell–cell adhesion, CD70 (encoding CD70, also known as tumor 
necrosis factor ligand superfamily member 7), (Oelke et al., 2004) which is required for T cell 
proliferation, clonal expansion and the promotion of effector T cell formation, and CD40LG 
(encoding CD40 ligand), (Lu et al., 2007) which stimulates B cell IgG overproduction.  
On the other hand in case of hypermethylation of promoter sequences, transcription factor-
binding sites have reduced binding affinity for their cognate transcription factors. Nielson et 
al (2009) examined whether there are differences in cytosine: guanine (CpG) dinucleotide 
methylation in the OPRM1 promoter between former heroin dependent subjects and 
controls. Analysis of methylation at 16 CpG dinucleotides in DNA obtained from 
lymphocytes of 194 Caucasian former severe heroin addicts stabilized in methadone 
maintenance treatment and 135 Caucasian control subjects revealed significant methylation 
differences at the -18 CpG and +84 CpG dinucleotide sites in the propmoter region of the 
OPRM1 gene. Both the -18 and the + 84 CpG sites are located in potential Sp1 transcription 
factor-binding sites. Methylation of these CpG sites may lead to reduced OPRM1 expression 
in the lymphocytes of these former heroin addicts and in turn impact the immune response 
mounted to both auto and external antigens.  
8. Failing to protect: Immune dysfunction spells trouble 
Immune suppression has been seen in patients suffering from heroin dependence (Naik et 
al., 2001). Opiate drug and its psychonutritional consequences have been reported to 
suppress movement and number of white blood cells (Perez-Castrillon et al., 1992; Herbert 
and Cohen, 1993; Scrimshaw and SanGiovanni 1997; Miyagi et al 2000). Opioid abuse is 
directly associated with some severe intestinal complications, including toxic megacolon, 
necrotizing enterides and necrotizing angiitis (Roszler et al., 1991). In addition, Gram-
negative enteric bacteria have been implicated as causative agents in enterococcal 
endocarditis and other severe infections associated with opiate abuse. Recent studies with 
MOR deficient mice support a physiological anti-inflammatory effect of MOR at the colon 
interface (Philippe et al., 2006). Exogenous morphine reduces IgA production in the 
intestinal tract of mice in response to oral administration of cholera toxin (Dinari et al., 
1989). Our own findings show that subjects with the prototypical A118A (AA) genotype are 
at a greater risk for active immuno-suppression by exogenous opiates. The marked 
reduction in circulating IgA observed in the AA genotype bearing dependent subjects 
suggests that such individuals could be at a higher risk for developing opiate-induced 
intestinal complications and/or defects in mucosal defence. This study also provides an 
insight into the probable molecular basis for differential adverse reactions, specifically 
gastrointestinal complications in different individuals. However, more studies are required 
to further elucidate whether MOR genotype differences contribute to an individual’s 
vulnerability to develop gastrointestinal disorders linked with opiate addictions and /or the 
course and outcome of inflammatory/infectious diseases due to active immuno-suppression 
by exogenous opiates. This review also provides an insight into the probable molecular basis 
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for differential adverse immune reactions and gastrointestinal complications in different 
individuals.  
9. Conclusion 
Opioid receptors are expressed in cells of the immune system, and potent 
immunomodulatory effects of their natural and synthetic ligands have been reported.  
Opiate drugs are known to possess direct suppressive effects on cellular and humoral 
immunity by influencing both the function of immunocompetent cells and inflammation 
mediator gene/s expression and secretion (Shin and Masato, 2008). In turn, the major source 
of local endogenous opioid ligands (beta-endorphin, enkephalins, endomorphins and 
dynorphin) are leukocytes themselves. Both in vivo and in vitro opioids affect activity of 
leukocytes and expression of inflammatory molecules, such as chemokines and chemokine 
receptors, in leukocytes. Chemokines induce cellular migration and are crucial players in 
initiating both innate  and adaptive immune response (Figure 7). 
A series of very early inflammatory events induce activation of tissue and endothelial cells 
and culminates in production of chemokines such as interleukin-8 (IL-8) that induce 
migration of neutrophils to the affected site where they inactivate pathogens by 
phagocytosis or release of microbicides (Shen et al., 2006). U87 (astrocytoma), normal 
human astrocyte (NHAs) (Neudeck and Loeb, 2002) and Caco2  (Neudeck et al., 2003) cells 
treated with morphine showed significant down-regulation of proinflammatory chemokines 
such as IL-8, MCP-1, and MIP-1 beta and this was inhibited by treatment with MOR 
antagonist, beta-funaltrexamine (Mahajan et al., 2005). 
Opioid receptors activate several intracellular pathways, such as closing of voltage-sensitive 
calcium channels, opening of potassium channels leading to cellular hyper-polarization and 
decrease in cyclic AMP production through inhibition of adenylate cyclase. Predominant 
channels found in lymphocytes are voltage-gated K+ channels and several lines of evidence 
suggest that these channels are involved in lymphocyte function/s. Vassou et al (2008) have 
suggested that the effects of opioids on B-lymphocytes may be attributed to interplay 
between distinct cell populations. Findings from our lab  show that the presence 118G allele 
not only impacts the amount of drug consumed, but also influences the immunomodulation 
caused by exogenous opiates. The individuals homozygous for AA genotype seem to be 
more vulnerable to suppression of humoral immunity (antibody production by B cells) while 
those with GG genotype could be protected against such depression of B-cell function. Indeed, 
Vassou et al. (2008) have shown that opiates like morphine, alphaS1-casomorphin and 
ethylketocyclazocine modulate antibody and cytokine secretion by multiple myeloma cells in a 
cell line-dependent manner and decrease antibody secretion by normal B-lymphocytes. Data 
from both transfected cells and human autopsy brain tissue from carriers of 118G allele 
indicate that this allele may produce deleterious effect on mRNA and corresponding MOR 
protein yield (Janicki et al., 2006). Based on the literature reviewed here it can be 
conclusively said that the complete repertoire of molecular consequence of the 118G SNP on 
receptor function in various immune cells and nevous tissue still remain unelucidated. A 
larger study to delineate the effect of AG and GG alleles on suppression of B cell function in 
the carriers, increasing susceptibility to consequent metabolic compromises leading to 
diseases and to establish the utility of of this SNP as a marker for estimating adverse 
immune-modulation in opiate dependent subjects and patients under treatment with opiate 
drugs needs to be undertaken in different ethnic populations world wide. 
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Fig. 7. Effect of opioid intake on immune system 
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